Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
SuperGen discontinues clinical development of SGI-1776 PIM kinase drug candidate

SuperGen discontinues clinical development of SGI-1776 PIM kinase drug candidate

Micromet to offer shares of common stock

Micromet to offer shares of common stock

TRU-016 abstracts to be presented at ASH meeting

TRU-016 abstracts to be presented at ASH meeting

Researcher awarded Sylvia and Charles Viertel Charitable Foundation Fellowship

Researcher awarded Sylvia and Charles Viertel Charitable Foundation Fellowship

Senior Scientific receives QTDP grants for cancer detection and treatment

Senior Scientific receives QTDP grants for cancer detection and treatment

EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010

EntreMed to present data of ENMD-2076 Phase 1 study in multiple myeloma and leukemia at ASH 2010

ARIAD reports $20.4 million net loss for third quarter 2010

ARIAD reports $20.4 million net loss for third quarter 2010

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

Semafore's SF1126 for B-cell chronic lymphocytic leukemia granted FDA orphan drug designation

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

EUSA completes BLA filing for ERWINASE in treatment of acute lymphoblastic leukemia

Children with JIA face increase risk of developing cancer

Children with JIA face increase risk of developing cancer

EpiCept third quarter net loss decreases to $3.2 million

EpiCept third quarter net loss decreases to $3.2 million

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

New data on Soliris for PNH treatment to be presented at ASH Annual Meeting

CytRx reports $4.4 million net loss for third quarter 2010

CytRx reports $4.4 million net loss for third quarter 2010

People with SLE more likely to develop hematologic malignancies

People with SLE more likely to develop hematologic malignancies

EpiCept to receive $1.9 million in net proceeds

EpiCept to receive $1.9 million in net proceeds

Skin to blood transformation in the lab

Skin to blood transformation in the lab

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

Synta reports $10.3M net loss for third quarter 2010 vs. $118.1M net income for third quarter 2009

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

EUSA Pharma announces 10-year outcome data of PROSTASCINT in prostate cancer radiotherapy

New findings show combinational therapy effective for patients with DLBCL lymphoma

New findings show combinational therapy effective for patients with DLBCL lymphoma

Low vitamin D levels linked to cancer progression and death in CLL patients

Low vitamin D levels linked to cancer progression and death in CLL patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.